Non-valvular Atrial Fibrillation
Conditions
Keywords
Atrial Fibrillation (AF), NVAF
Brief summary
While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel supplying blood to the brain is obstructed), bleeding or thromboembolism (a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel), limited data are available on the number of NVAF patients and the reasons why NVAF patients in Italy stop or change their treatment with blood thinners to prevent stroke or thromboembolism. By following the NVAF patients in routine clinical practice in Italy who are treated with rivaroxaban to prevent stroke or systemic embolism researchers want to find out how many NVAF patients and for what reasons NVAF patients stopped or changed rivaroxaban treatment. Study data will be collected through patients' routine visits at their treating doctor over a period of 24 months for each patient.
Interventions
DRUGRivaroxaban (Xarelto, BAY59-7939)
Treatment dose is following the description of physicians.
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 * Patient with a diagnosis of NVAF * New user to rivaroxaban, naïve or non naïve to treatment with oral anticoagulant * Patient for whom the decision to initiate treatment with rivaroxaban was made as per physician's routine treatment practice for prevention of stroke and non-central nervous system (CNS) systemic embolism * Signed an informed consent
Exclusion criteria
* Patient with heart valve replacement * Patient is participating in an investigational program with interventions outside of routine clinical practice
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Date of start of rivaroxaban treatment | 24 months |
| Date of stop of rivaroxaban treatment | 24 months |
| Number of patients who discontinue (i.e: number of discontinuation) from study initiation to end of observation/follow up. | 24 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reason for switch to other therapy | 24 months | * Ischemic event * Bleeding and site of bleeding * Adverse drug reaction * Drug interaction with other therapies * New treatment after switch |
| Reason for dose change of rivaroxaban therapy | 24 months | * Change in Creatinine Clearance (CrCL) * Insufficient therapeutic effect * Adverse event |
| Treatment adherence: Self-reported medication adherence measured by the MMAS-8 (Morinsky Scale score) | 24 months | — |
| Reasons for discontinuation of rivaroxaban therapy | 24 months | * therapy discontinuation due to adverse event (AE) * therapy discontinuation for non AE related reason * physician decision * patient lost to follow up, no remote contact * patient decision (not related to AE) * patient is in stable sinus rhythm * patient decided to terminate study participation but agreed to further use of data collected so far. * patient decided to terminate study participation and refused further use of collected data. * Patient died * Treatment switch |
Countries
Italy
Outcome results
None listed